MedTrace Logo

CyberKnife Radiosurgery for Localized Prostatic Carcinoma

NCT01045148 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2017-07-21

No results posted yet for this study

Summary

Virtual high dose rate (HDR) CyberKnife (CK) prostate treatment has comparable morbidity and efficacy compared with actual prostate HDR treatment, but does it without the catheters and hospital admission. As such, it is a more "patient friendly" treatment method compared with actual prostate HDR brachytherapy as currently practiced. Related, as has previously been reported with actual prostate HDR treatment, Virtual HDR CyberKnife prostate treatment should have a high efficacy but with lower acute and chronic morbidity compared with other local prostate cancer treatment methods such as permanent seed prostate brachytherapy.

Conditions

Interventions

RADIATION

CyberKnife Radiosurgery

High Dose 3800 cGy/4 fractions

RADIATION

CyberKnife Radiosurgery

Moderate Dose 3400 cGy/5 fractions

Sponsors & Collaborators

  • CyberKnife Centers of San Diego

    lead OTHER

Principal Investigators

  • Donald B Fuller, M.D. · CyberKnife Centers of San Diego/Radiation Medical Group- Genesis Healthcare Partners

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01045148 on ClinicalTrials.gov